You are here

Home » Content

EVALUATION OF THE UTILIZATION OF ORAL HYPOGLYCEMIC DRUGS IN DIABETIC TYPE 2 OUTPATIENT CLINIC OF A TEACHING HOSPITAL IN NORTH INDIA

Journal Name:

  • The International Journal of Pharmaceutical Research and Bio-Science

Publication Year:

  • 2013

Key Words:

Author Name
Abstract (2. Language): 
Diabetes Mellitus is a metabolic disorder characterized by the presence of hyperglycaemia due to defective insulin secretion, insulin action or both. The estimated number of people with diabetes registered in India was 50.8 million in the 2010 and diabetes will be affecting 87 million persons by 2030. A prospective cross-sectional study was conducted in the outpatient Department of Medicine in "TEERTHANKER MAHAVEER HOSPITAL", Moradabad, U.P. Proper informed consent was obtained from all patients. Among all the drugs prescribed to Type 2 DM patients, 43.4% were found to be anti-diabetic drugs. The most prescribed drugs were sulphonylureas (50.4%). Biguanides were the second most prescribed drugs (46.6%). In our study, maximum patients were prescribed combination therapy of two or more oral anti diabetic drugs (44.7%). A firm conclusion of this study strongly highlights the need for patient education or counseling on use of antidiabetic and concomitant drugs, monitoring of blood glucose and glycosylated haemoglobin (HbAlc) levels, dietary modification with low calorie food, and correction of diabetic complications.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon ijprbs_352.pdf
  • 3
248-259
  • English

REFERENCES

References: 

1. Clinical practice guidelines for the management of diabetes in Canada 1998. Supplement to Canadian Medical Association Journal 59 (8 Suppl), 1998.
2. Kahn SE, Porte D Jr.: The pathophysiology of type 2 diabetes mellitus: implications for treatment. In: Porte D Jr. Sherwin RS. Ellengerg's and Rafkin's Diabetes Mellitus 5th Ed. Stanford, CT: Appleton & Lange, 487, 1997.
3. Hammond and Levine: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 285-295.
4. Sicree R, Shaw J, Zimmet P: Diabetes and impaired glucose tolerance .In:Gan D, editor. Diabetes Atlas. International Diabetes Federation. 3rd ed. International Diabetes Federation; Belgium: 15-103, 2006.
5. Wysowski DK, Armstrong G, Governale L: Rapid Increase -in the Use of Oral Antidiabetic Drugs in the United States,
1990-2001. Diabetes Care 26: 1852-1855, 2003.
6. Hofmann CA, Colca JR: New oral thiazolidinedione antidiabetic agents act as insulin sensitizers. Diabetes Care 15:1075¬1078, 1992.
7. Andre JS, Pierre JL: Potential Pharmacokinetics Interference between a-Glucosidase Inhibitors and Other Oral Antidiabetic Agents. Diabetes Care 25:247¬248.2002.
8. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2diabetes: UKPDS 38. British Medical Journal 317:703, 1998.
9. Sultana G, Kapur P, Aqil M, Alam MS, Pillai KK: Drug utilization of oral hypoglycemic agents in a university teaching hospital in India. J Clin Pharm Ther, 35(3): 267-77; 2010.
10. Weekes AJ, Thomas MC: The use of oral antidiabetic agents in primary care. Aust Fam Physician, 36(6):477-80; 2007.
11. Winkelmayer WC, Stedman MR, Pogantsch M, Wieninger P, Bucsics A, Asslaber M, Bauer R, Burkhardt
Available Online At www.ijprbs.com
Research Article
Sanjeev Sharma, IJPRBS,
2013; Volume 2(3): 248-259
ISSN: 2277-8713
IJPRBS
T, Schautzer A, Brookhart
MA: Pharmacoeconomics Advisory Council of the Main Association of Austrian Sickness Funds, Guideline-conformity of initiation with oral hypoglycemic treatment for patients with newly therapy-dependent type 2 diabetes mellitus in Austria., Pharmacoepidemiol Drug Saf.,
20(1):57-65; 2011.
12. Kabadi UM: Cost-effective management of hyperglycemia in patients with type 2 diabetes using oral agents. Manag Care,
13(7):48-9, 53-6, 58-9; 2004.
13. Mori RC, Hirabara SM, Hirata AE, Okamoto MM, Machado UF: Glimepiride as insulin sensitizer: increased liver and muscle responses to insulin.
Diabetes Obes Metab. 10(7):596-600; 2008.
14. Umpierrez G, Issa M, Vlajnic A: Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy, Curr Med Res
Opin.; 22(4):751-9, 2006.
15. Klarenbach S, Cameron C, Singh S, Ur E: Cost-effectiveness of second-line
antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin;
CMAJ ;183(16):E1213-20, 2011.
16. Plat A, Penning-van Beest F, Kessabi S, Groot M, Herings R: Change of initial oral antidiabetic therapy in type 2 diabetic patients.. , Pharm World Sci.,
31(6):622-6; 2009.
17. Patel M, Patel IM, Patel YM, Rathi SK.: A hospital-based observational study of type 2 diabetic subjects from Gujarat, India; J Health Popul Nutr; 29(3):265-72, 2011.

Thank you for copying data from http://www.arastirmax.com